India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#99- Valuation
- ₹68,150 Cr
2023 #74 2022 #65 2021 #81
Revenue · FY 2026
₹15,434 Cr
▲ 33% YoY
Net profit · FY 2026
₹1,542.54 Cr
Net margin 10%
EBITDA · FY 2026
₹4,371.3 Cr
EBITDA margin 28.3%
Authorised capital
₹175.47 Cr
Registered with MCA
Paid-up capital
₹114.77 Cr
Issued & subscribed
Open charges
₹4.5 Cr
Satisfied ₹7,924.94 Cr
Company age
41 yrs
Est. 1985
Employees · EPFO
19,974
Provident fund records
About Intas Pharmaceuticals Limited
Data last updated:
Intas Pharmaceuticals Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 31 May 1985 and has been in existence for over 41 years.
Its director Urmish Hasmukh Chudgar and family are #197 among India's richest people (2026). Its director Binish Hasmukh Chudgar and family are #197 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN U24231GJ1985PLC007866. Its GSTIN is 24AAACI5120L1ZU (Gujarat). The company holds 31 GST registrations, of which 26 are active.
The company has an authorised share capital of ₹175.47 Cr and a paid-up capital of ₹114.77 Cr. It was formerly known as Intas Laboratories Private Limited. It is led by directors including Urmish Hasmukh Chudgar (Managing Director) and Binish Hasmukh Chudgar (Managing Director).
Its last annual general meeting (AGM) was held on 31 July 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Corporate House Near Sola Bridge S. G. Highway Thaltej, Ahmedabad, Gujarat, India – 380054.
As per the financials filed for FY 2026, the company reported a revenue of ₹15,434 Cr, a growth of 33% compared to the previous year. For the same year it recorded a net profit of ₹1,542.54 Cr (net margin 10%) and EBITDA of ₹4,371.3 Cr (EBITDA margin 28.3%). Revenue has grown at a compounded annual rate (CAGR) of 12% over three years and 11% over five years.
The company has about 19,974 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Intas Animal Health and Intas. As per MCA filings, the company has open charges of ₹4.5 Cr and satisfied charges of ₹7,924.94 Cr on record. Court records list 1,073 cases involving the company, including 781 filed by the company and 293 filed against it; 283 cases are pending. The company has 15 deals on record (9 secondary share transfers, 6 funding rounds), with disclosed funding of ₹347.58 Cr; the latest was in March 2025. Its 9 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 4 smaller; the largest is Dr.Reddy's Laboratories Ltd with revenue of ₹33,741 Cr. The company has 15 MSME Form 1 returns on record between 2017 and 2024, listing 4,786 overdue payments to 477 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website intaspharma.com.
Company details
CIN U24231GJ1985PLC007866
Registration Number 007866
Incorporation Date 31 May 1985
ROC Ahmedabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 31 July 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
CIN history
Intas Pharmaceuticals has one previous CIN (Corporate Identification Number): U24231GJ1985PTC007866. The current CIN is U24231GJ1985PLC007866, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24231GJ1985PLC007866 | Current |
| U24231GJ1985PTC007866 | Previous |
Key People
Urmish Hasmukh Chudgar Managing Director Binish Hasmukh Chudgar Managing Director Nimish Chudgar Managing Director Recognitions & Rankings of Intas Pharmaceuticals
India's Richest People 2026 edition · 4 directors · Source: Hurun India
- #197 Urmish Hasmukh Chudgar & family ₹18,300 Cr
- #197 Binish Hasmukh Chudgar & family ₹18,300 Cr
- #202 Nimish Hasmukh Chudgar & family ₹18,200 Cr
+1 more
Contact details
Intas Pharmaceuticals Limited's registered office is in Ahmedabad, Gujarat. Its website is intaspharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressCorporate House Near Sola Bridge S. G. Highway Thaltej, Ahmedabad, Gujarat, India – 380054
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Intas Pharmaceuticals Limited, buy the company report.
Comprehensive company report
Intas Pharmaceuticals Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Intas Pharmaceuticals operates two associated brands: Intas Animal Health and Intas. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Animal healthcare products and services are provided by the company in veterinary and pharmaceutical sectors. | intasanimalhealth.com | |
| Formulation development, drug manufacturing, and marketing services are provided. | intaspharma.com |
Business activity
The main business activity of Intas Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Intas Pharmaceuticals Limited, buy the company report.
Financials of Intas Pharmaceuticals Limited
FY 2026 filings availableIntas Pharmaceuticals Limited reported revenue of ₹15,434 Cr (up 33% YoY) for FY 2026.
Revenue · FY 2026
₹15,434 Cr ▲ 33%
Net profit · FY 2026
₹1,542.54 Cr margin 10%
EBITDA · FY 2026
₹4,371.3 Cr margin 28.3%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 33%
3 years · compounded
▲ 12%
5 years · compounded
▲ 11%
EBITDA CAGR growth
1 year
▲ 50%
3 years · compounded
▲ 6%
5 years · compounded
▲ 3%
Revenue has grown at a compounded annual rate (CAGR) of 11% over five years, including 33% growth in the latest year. EBITDA rose 50% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹15,434 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹4,371.3 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1,542.54 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 28.3% | ||||
| Net Profit Margin | 10% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Intas Pharmaceuticals Limited, buy the company report.
Board of directors of Intas Pharmaceuticals Limited
Intas Pharmaceuticals has 9 current directors and 17 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Hasmukh Chudgar | Director | 31 May 1985 | 41 Years 4 Months | Current |
| Jayesh Shantilal Shah | Whole-Time Director | 21 Mar 2018 | 8 Years 7 Months | Current |
| Urmish Hasmukh Chudgar Also directs: Advanced Transfusion Medicine Research Foundation, Astron Packaging Limited, Accord Healthcare Limited and 3 more | Managing Director | 30 Sep 1996 | 30 Years 0 Months | Current |
| Binish Hasmukh Chudgar Also directs: Astron Packaging Limited, Accord Healthcare Limited, Jina Lifesciences Private Limited and 5 more | Managing Director | 31 May 1985 | 41 Years 4 Months | Current |
| Nimish Chudgar Also directs: Astron Packaging Limited, Accord Healthcare Limited, SM Herbals Private Limited and 2 more | Managing Director | 31 May 1985 | 41 Years 4 Months | Current |
| Ratnasami Venkatesh Also directs: Delta Innovative Research LLP | Nominee Director | 13 Nov 2014 | 11 Years 11 Months | Current |
Showing 6 of 9 current directors. View all directors
Peer comparison
Intas Pharmaceuticals Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Dr.Reddy's Laboratories Ltd | ₹33,741 Cr (FY 2025) | 17.0% | Hyderabad, Telangana, India | |||
| Aurobindo Pharma Ltd | ₹32,346 Cr (FY 2025) | 9.0% | Hyderabad, Telangana, India | |||
| Cipla Limited | ₹28,409 Cr (FY 2025) | 7.0% | Mumbai, Maharashtra, India | |||
| Zydus Lifesciences Limited | ₹23,511 Cr (FY 2025) | 19.0% | Ahmedabad, Gujarat, India | |||
| Lupin Limited | ₹22,904 Cr (FY 2025) | 14.0% | Mumbai, Maharashtra, India | |||
| Hetero Labs Limited | ₹16,537 Cr (FY 2025) | 13.0% | Hyderabad, Telangana, India | |||
| Biocon Limited | ₹16,470 Cr (FY 2025) | 5.0% | Bengaluru, Karnataka, India | |||
| Intas Pharmaceuticals Limitedthis company | ₹15,434 Cr (FY 2026) | ₹1,542.54 Cr | 10% | 33.0% | 19,974 | Ahmedabad, Gujarat, India |
| Alkem Laboratories Limited | ₹13,458 Cr (FY 2025) | 4.0% | Mumbai, Maharashtra, India | |||
| Glenmark Pharmaceuticals Limited | ₹13,435 Cr (FY 2025) | 6.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Intas Pharmaceuticals Limited, buy the company report.
Auditor
Intas Pharmaceuticals Limited is audited by S R B C & CO LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| S R B C & CO LLP | FY 2023 | 324982E/E300003 |
Shareholding
The shareholding of Intas Pharmaceuticals Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Intas Pharmaceuticals Limited, buy the company report.
Charges & borrowings
Open charges
₹4.5 Cr
Satisfied charges
₹7,924.94 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 01 May 1998 | 90107682 | Dena Bank | ₹4.5 Cr | Open | |
| 04 Sep 2017 | 100125104 | Standard Chartered Bank | ₹184.62 Cr | Satisfied | |
| 28 Dec 2016 | 100071690 | Others | ₹3,218.29 Cr | Satisfied | |
| 28 Dec 2016 | 100072051 | Others | ₹1,845.87 Cr | Satisfied | |
| 21 Mar 2016 | 100019286 | Citi Bank N.A. | ₹115 Cr | Satisfied |
To see the full charge records of Intas Pharmaceuticals Limited, buy the company report.
Total charge records: 82 View all charges
Deals & funding
Intas Pharmaceuticals Limited has 15 deals on record (9 secondary share transfers, 6 funding rounds), with disclosed funding of ₹347.58 Cr; the latest was in March 2025.
Total deals
15
Secondary share transfers
9
Funding rounds
6
Disclosed funding
₹347.58 Cr
Deals on record (5 of 15)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2025 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: 2 individuals |
| Oct 2022 | Secondary share transfer | Undisclosed | Buyer: Abu Dhabi Investment Authority PE Seller: Temasek |
| Mar 2017 | Secondary share transfer | Undisclosed | Buyer: Capital Group Private Markets Seller: ChrysCapital Investment Advisors India |
| Nov 2010 | Secondary share transfer | Undisclosed | Seller: Parikh Dave & Associates- Thr Its Partners (Trustees), Udaysinh Patankar (Huf), 2 individuals |
| Mar 2009 | Secondary share transfer | Undisclosed | Seller: Dolphin Laboratories Ltd , Chandrakant Gandhi(Huf), 2 individuals |
To see the full deal history of Intas Pharmaceuticals Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Intas Pharmaceuticals Limited has 1,073 court cases on record: 781 filed by Intas Pharmaceuticals, 293 filed against it. 283 cases are pending and 790 are disposed.
Total cases
1,073
Filed by the company
781
Filed against the company
293
Pending
283
Disposed
790
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 659 | 81 | 196 |
| High courts | 375 | 176 | 71 |
| Supreme Court | 22 | 20 | 4 |
| NCLAT | 14 | 13 | 11 |
| NCLT | 3 | 3 | 1 |
Cases on record (5 of 1,073)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Supreme Court | Court case (2902-Labour and Industrial Laws : Payment of wages, bonus, provident fund, gratuity, service benefits, benefits under ESIC Act, 1948, compensation under Workmen's Compensation Act, 1923 (now Employees Compensation Act, 1923)and payment of overtime wages and minimum wage.) | Filed against the company by an individual | Disposed |
| Supreme Court | Court case (2406-Indirect Taxation : Goods and Services Tax, Integrated Goods and Services Tax, State Goods and Services Tax, UT Goods and Services Tax.) | Filed against the company by Union of India and 2 others | Disposed |
| District court, Ahmedabad, Gujarat | Criminal complaint | Filed by the company against Yolo Eximcare Pvt. Ltd. | Pending |
| District court, Ahmedabad, Gujarat | Commercial matter | Filed by the company against Usv Private Limited Through Its M.D. Prashant Kumar Tewari | Pending |
| High Court of Delhi | Commercial suit | Filed against the company by Dr. Reddys Laboratories Limited | Pending |
To see the full case history of Intas Pharmaceuticals Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Intas Pharmaceuticals Limited was last rated by Care on 07 Apr 2022.
| Rating agency | Rated on | Rating |
|---|---|---|
| Care | 07 Apr 2022 |
To see the full credit ratings and regulatory alerts of Intas Pharmaceuticals Limited, buy the company report.
MSME payment delays
Intas Pharmaceuticals Limited has 15 MSME Form 1 returns on record between 2017 and 2024, listing 4,786 overdue payments to 477 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 477)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Synokem Lifesciences Private Limited | |||
| Melody Healthcare Private Limited | |||
| Panchsheel Organics Limited | |||
| an individual supplier | |||
| Futuristic Packaging Private Limited |
To see the full MSME payment records of Intas Pharmaceuticals Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Intas Pharmaceuticals Limited has a workforce of 19,974 employees on its EPFO records as of Feb 28, 2025, across 4 active EPFO establishments.
Employee count
19,974
Active EPFO establishments
4
Employee growth
8.32%
GST
Intas Pharmaceuticals has 31 GST registrations: 26 active and 5 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
31
Active
26
Cancelled / inactive
5
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAACI5120L1ZU | Gujarat | Active | 01 Jul 2017 |
| 24AAACI5120L3ZS | Gujarat | Active | 01 Jul 2017 |
| 24AAACI5120L2ZT | Gujarat | Active | 05 Jul 2017 |
| 24AAACI5120L4ZR | Gujarat | Active | 08 Jul 2017 |
To see the full GST registrations and return filing status of Intas Pharmaceuticals Limited, buy the company report.
Recent activity
Intas Pharmaceuticals Limited has 25 board changes on record since 1985: 10 appointments and 15 cessations. The latest: Binish Hasmukh Chudgar ceased to be Managing Director on 30 Sep 2024.
AGM
Intas Pharmaceuticals Limited last Annual general meeting of members was held on 31 Jul 2026 as per latest MCA records.
Filing
Intas Pharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Charges
A charge registered on 25 Jun 1999 via Charge ID 90103163 with Others was fully satisfied on 01 Oct 2024.
Ceased
Binish Hasmukh Chudgar ceased to be Managing Director.
Appointed
Jitesh Kishorekumar Gadhia was appointed as Director.
Appointed
Rakesh Bamzai was appointed as CEO.
Ceased
Archana Ravindrarai Dholakia ceased to be Additional Director.
Appointed
Archana Ravindrarai Dholakia was appointed as Director.
Ceased
Tushar Dhansukh Shroff ceased to be Cfo(Kmp).
Charges
A charge registered on 28 Dec 2016 via Charge ID 100072051 with Others was fully satisfied on 30 Nov 2021.
Charges
A charge registered on 28 Dec 2016 via Charge ID 100071690 with Others was fully satisfied on 04 Aug 2021.
Charges
A charge registered on 04 Sep 2017 via Charge ID 100125104 with Standard Chartered Bank was fully satisfied on 03 Aug 2020.
229 earlier events are in the company report.
News
From our blog
Frequently asked questions
Intas Pharmaceuticals is an active public limited company based in Ahmedabad, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 31 May 1985 (41+ years old) and is registered under CIN U24231GJ1985PLC007866.
Intas Pharmaceuticals has 9 current directors:
- Urmish Hasmukh Chudgar - Managing Director
- Binish Hasmukh Chudgar - Managing Director
- Nimish Chudgar - Managing Director
- Jayesh Shantilal Shah - Whole-Time Director
- Hasmukh Chudgar - Director
- Ratnasami Venkatesh - Nominee Director
- Sanjay Kukreja - Director
- Jitesh Kishorekumar Gadhia - Director
- Archana Ravindrarai Dholakia - Director
The latest financial statements of Intas Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 31 July 2026. Year-wise statements from 2015 are in the company report.
The GSTIN of Intas Pharmaceuticals is 24AAACI5120L1ZU, registered in Gujarat. The company has 31 GST registrations in all, of which 26 are active and 5 are cancelled or inactive. Other active GSTINs include 24AAACI5120L3ZS (Gujarat), 24AAACI5120L2ZT (Gujarat), 24AAACI5120L4ZR (Gujarat).
The CIN (Corporate Identification Number) of Intas Pharmaceuticals is U24231GJ1985PLC007866. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Intas Pharmaceuticals has 1,073 court cases on record: 781 filed by the company and 293 filed against it. 283 are pending. Most are in the district courts.
Intas Pharmaceuticals was incorporated on 31 May 1985, making it 41+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Intas Pharmaceuticals has 15 deals on record (9 secondary share transfers, 6 funding rounds), with disclosed funding of ₹347.58 Cr; the latest was in March 2025.
The peers of Intas Pharmaceuticals by revenue are Dr.Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, Cipla Limited, Zydus Lifesciences Limited, Lupin Limited and 4 more, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Binish Hasmukh Chudgar ceased to be Managing Director on 30 Sep 2024. Jitesh Kishorekumar Gadhia was appointed as Director on 19 Sep 2024. Rakesh Bamzai was appointed as CEO on 19 Sep 2024. Intas Pharmaceuticals has 25 board changes on record in total.
Intas Pharmaceuticals has 15 MSME Form 1 returns on record between 2017 and 2024, listing 4,786 overdue payments to 477 micro and small suppliers. The latest return was filed on 29 Apr 2024.
Intas Pharmaceuticals can be reached through the website intaspharma.com. Its registered office is in Ahmedabad, Gujarat, India.